Companies say the new messenger RNA technology first used on a large scale in their Covid vaccines will allow flu vaccines to be developed faster to match the ever-changing annual strains and improve efficacy rates.
The possible large-scale entry of these giants into the flu vaccine market has also forced traditional companies such as Sanofi, Seqirus and GlaxoSmithKline to accelerate their research on mRNA alternatives, even though these companies claim that their existing products are -could still prove superior.
Why are Pfizer and Moderna targeting the flu vaccine market?
According to the Fortune Business Insights research group, this already large market is expected to grow by 7.2% per year, reaching $ 10.7 billion in 2028. Another forecast puts the market at $ 17 billion by 2030.
As people became more aware of the threat of respiratory viruses – and the potential of vaccines to protect them – the revenues of the top three flu vaccine manufacturers increased by 23 to 35% between 2019 and 2020. About 40 percent of Sanofi’s revenue from 6 Billions in vaccines last year came from flu shots, the Financial Times reports.
Why might mRNA technology be revolutionary for flu vaccines?
Currently, every year, the World Health Organization has to predict which strains of the flu will circulate next winter. With the current flu vaccines, they have been making this choice since February – to give manufacturers time to make traditional vaccines, which require significant time.
MRNA technology, which uses the genetic code of the virus, is much faster than older technologies. This would allow a vaccine to be developed much later in the year. Thus, the researchers would know much better what strain of flu is circulating in that year and could adapt the vaccine.
COVID vaccine and flu combined?
Moderna announced the first data showing that its candidate vaccine against influenza increased the level of antibodies in a phase 1 study, even for the participants who received the lowest dose. Pfizer and BioNTech began enrolling participants in their Phase 1 study in September.
Stephen Hoge, president of Moderna, told investors that the vaccine candidate is just a starting point.
He is a “big supporter” of the potential benefits of combining flu and Covid vaccines in a single injection.
The mRNA could be used to combine a vaccine against the four annual influenza strains considered a priority by the WHO, the current variant of Sars CoV-2 and the respiratory syncytial virus, which can be serious for infants and the elderly. Moderna tested the inclusion of six different mRNA sequences in a single dose in a cytomegalovirus vaccine.
“We believe that people will not take three different doses. One injection for pan-respiratory protection seems to be the right answer, “Hoge told FT.
–
For the most important news of the day, broadcast in real time and presented equidistantly, LIKE our Facebook page!
Follows Mediafax on Instagram to see spectacular images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your personal information and use. It is prohibited republishing the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, please contact us at [email protected].
